Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up

European Journal of Surgical Oncology

Volumn 29, Issue 9, 2003, Pages 707-710

  Kelly, L M ^a   Hill, A D K ^a   Kennedy, S ^a   Connolly, E M ^a   Ramanath, R ^a   Teh, S ^a   Dijkstra, B ^a   Purcell, R ^a   McDermott, E W ^a   O'Higgins, N ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Breast cancer; Cyclo oxygenase; Survival

Indexed keywords

CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN; POLYCLONAL ANTIBODY; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PATHOLOGIST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TISSUE SECTION; TUMOR VOLUME;

EID: 0345327752     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2003.07.001     Document Type: Article

References (23)

1. Harrris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (first of three parts). N Engl J Med 1992; 327(5): 319-28.
2. Visscher DW et al. Clinical significance of pathologic, cytometric, and molecular parameters in carcinoma of the breast. Adv Pathol Lab Med 1992; 5: 123.
3. Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G, Harris RE. Ibuprofen-induced inhibition of cyclo-oxygense isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 1998; 122: 165-75.
4. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24(Suppl. 49): 15-19.
5. Bjorkman DJ. The effects of asprin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med 1998; 105(IB): 8S-12S.
6. Mitchell JA, Evans TW. Cyclooxygenase as a therapeutic target. Inflamm Res 1998; 47(Suppl. 2): S88-S92.
7. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclo-oxygenase 2 inhibitor. Cancer Res 2000; 60: 2101-3.
8. Schreinemachers DM, Everson RB. Asprin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138-46.
9. Harris RE, Namboodiri KK, Farrar WB. Non-steroidal anti-inflammatory drugs and cancer. Epidemiology 1996; 7: 203-5.
10. Sharpe CR, Collet JP, McNutt M et al. Nested case-control study of the effects of nonsteroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000; 83: 112-20.
11. Khoo NKS, Chan FPH, Saarlos MN, Lala PK. Immunotherapy of mammary adenocarcinoma metastases in CH/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2. Clin Exp Metastasis 1992; 10: 239-52.
12. Sheehan KM, Sheahan K, O'Donoghue et al. The relationship between cyclo-oxygenase expression and colorectal cancer. JAMA 1999; 282: 1254-7.
13. Soslow RA, Dannenberg AJ, Rush D et al. Cox-2 is expressed in human pulmonary, colonic and mammary tumours. Cancer 2000; 89: 2637-45.
14. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992; 20(6): 479-89.
15. Lambkin HA, Dunne P, McCarthy PM. Standardisation of oestrogen receptor analysis by immunohistochemistry: an assessment of intra laboratory performance in Ireland. Appl Immunohistochem 1998; 6: 103-7.
16. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H et al. Expression of cyclo-oxygenase -1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-9.
17. Hwang DH, Scollard D, Byrne J, Levine E. Expression of cyclo-oxygenase-1 and cyclo-oxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455-60.
18. Brueggemeier RW, Quinn AL, Parrett ML, Farahnaz SJ, Harris RE, Robertson FM. Correlation of aromatase and cyclo-oxygenase gene expression in human breast cancer specimens. Cancer Lett 1999; 140: 27-35.
19. Rolland PH, Martin PM, Jacquemier J et al. Prostaglandins in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980; 64: 1061.
20. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying non-steroidal anti-inflammatory drug-mediated apoptosis. PNAS 1998; 95: 681-6.
21. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colonic cells. Cancer Res 1998; 58: 362-6.
22. Harris RE, Robertson FM, Abou-Issa HM, Farraf WB, Brueggemeier R. Genetic Induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer. Med Hypotheses 1999; 52: 291-2.
23. Gately S. The contributions of cyclo-oxygenase-2 to tumour angiogenesis. Cancer Metastasis Rey 2000; 19: 19-27.